Setrobuvir

Description: Setrobuvir (ANA-598) is an orally active non-nucleoside HCV NS5B polymerase inhibitor with inhibitory effects on de novo RNA synthesis and primer extension with IC50s between 4 and 5 nM. setrobuvir shows good binding affinity for SARS-CoV-2 RdRp and induces inhibition of RdRp. Target: HCV Protease, DNA/RNA Synthesis, SARS-CoV. Smiles: C(N1[C@@]2([C@@]([C@@]3(C[C@]2(CC3)[H])[H])(C(O)=C(C1=O)C=4NC=5C(S(=O)(=O)N4)=CC(NS(C)(=O)=O)=CC5)[H])[H])C6=CC=C(F)C=C6. References: Yi G, et al. Biochemical study of the comparative inhibition of hepatitis C virus RNA polymerase by VX-222 and filibuvir. Antimicrob Agents Chemother. 2012 , 56(2):830-837.